|Articles|February 15, 2003

BioPharm International-02-01-2003
Volume 16
Issue 2

Becoming a Partner of Choice and Evaluating Prospective Alliances

by David Wallis, Dechert and Jan Heybroek Whether you're on the inlicensing or outlicensing side of a collaboration, attention must be paid to putting forth the right image and learning about your prospective partners before the alliance is struck.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

over 23 years ago

Article

Using Amino Acid Analysis to Determine Absorptivity Constants: A Validation Case Study Using Bovine Serum Albumin

over 23 years ago

Article

Guest Editorial: Maybe You Need a Corporate Marriage Counselor

over 23 years ago

Article

Inside Washington: AIDS Prevention Campaign Spotlights Biotech

over 23 years ago

Article

The Double Helix at 50: A Half Century of Innovation in the Words of Eight Distinguished Scientists

over 23 years ago

Article

Survival Strategies: Keeping Tabs on Training

over 23 years ago

Article

Biotech World: Contract Manufacturing: Diversity in the European Marketplace

over 23 years ago

Article

Outsourcing Outlook: Contract Services' Crystal Ball

over 2023 years ago

Article

Virus Inactivation in the 1990s ? and into the 21st Century: Part 5: Disinfection

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

3D illustration of three golden spherical nanoparticles, one shown in cross-section to reveal a layered lipid shell, with a blue helical nucleic acid strand winding around them against a black background. | Image Credit: © Love Employee - stock.adobe.com

October 2nd, 2026

Novartis Licenses Abogen's mRNA-Encoded CD19xCD3 T-Cell Engager ABO2203 for Autoimmune Diseases

Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on Abogen's RNA platform.

Tablet, science team and people learning for cancer cure, help or medical development in laboratory. Training, investigation or research info with scientists in clinical trial for medicine internship | Image credit: © CoetzeeRising/peopleimages.com - © CoetzeeRising/peopleimages.com - stock.adobe.com

October 2nd, 2026

CaseBioscience Joins $7.3 Million ARPA-H Team on Cell Preservation

The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.

antibody-drug conjugation modality impacts overall therapeutic efficacy in brain tumors 3d rendering | Image credit: © Love Employee - © Love Employee - stock.adobe.com

October 2nd, 2026

AstraZeneca, Daiichi Sankyo, and Summit to Combine Datroway, Ivonescimab

A planned phase 3 trial will test the TROP2 ADC and PD-1/VEGF bispecific together in 1st-line triple-negative breast cancer.

A monoclonal antibody (mAb or moAb) is an antibody made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell. Coronavirus. 3d render | Image credit: © Naeblys - © Naeblys - stock.adobe.com

October 1st, 2026

Regeneron, Sanofi Expand Alliance with $1 Billion Upfront, 4 Antibodies

Sanofi is paying Regeneron up to $8 billion to co-develop REGN20423 and 3 other long-acting antibodies beyond dupilumab (Dupixent).

Three injection pens labeled Wegovy, Ozempic, and Victoza crossed behind a bottle of Wegovy semaglutide 1.5 mg tablets on a white background. | Image Credit: © silukstockimages - stock.adobe.com

September 29th, 2026

Novo Nordisk Licenses Hengrui's Once-Weekly Oral GLP-1/GIP Dual Agonist HRS-1596 in Deal Worth Up to $2.6 Billion

Novo gains global rights, excluding Greater China, to HRS-1596, a phase 1-ready GLP-1/GIP dual receptor agonist that Hengrui says has potential for once-weekly oral dosing in obesity and type 2 diabetes.

Colorful chain of amino acids or bio molecules called proteins - 3d illustration | Image credit: © Christoph Burgstedt - © Christoph Burgstedt - stock.adobe.com

September 25th, 2026

Earendil Labs Inks $1.5 Billion Bispecific Antibody Pact with Genentech

Genentech is paying Earendil Labs $55 million upfront in a deal worth over $1.5 billion to develop bispecific antibodies for hard-to-treat cancers.

September 24th, 2026

BIIE Aims to Be a Global Immune Engineering Embassy

Dr Stephen Wilson, CEO of the Botnar Institute of Immune Engineering, describes Basel's collaborative ecosystem and a 3-year roadmap linking research to global clinical partners.

Science, teamwork and scientist with tablet in laboratory for communication, pharmaceutical review or planning. Employees, collaboration and technology | Image credit: © Coetzee/peopleimages.com - © Coetzee/peopleimages.com - stock.adobe.com

September 24th, 2026

InnoCare Signs Research Deal With Lilly Worth Up to $3.35 Billion

InnoCare will discover compounds against up to 5 targets for Lilly, backing a deal worth up to $3.35 billion in milestones.